Objective: This assessment depicts the strength of exhibiting reverse-phase high performance liquid chromatography (RP-HPLC) method for the estimation of torsemide in pharmaceutical estimation structures.
INTRODUCTION
1-Isopropil-3-[4-(3-methylphenylamino)-3-pyridinesulphonyl] urea (torsemide) is the most dynamic agent of the novel anilinopyridine sulfonylurea subsidiaries class diuretics. It has been found to have impacts on water and electrolyte discharges. As a result of its site of activity obstructing the sodium and chloride reabsorption at the circle of Henle, it tends to be arranged by definition as a circle diuretic. Likewise, its diuretic profile intently takes after that of circle diuretics. Be that as it may, as opposed to the common circle diuretics of the furosemide type, torsemide demonstrates a few points of interest by its generously longer organic half-life, longer term of activity, and significantly less articulated kaliuretic and phosphaturic impacts. Torsemide is appropriate for a wide range of various signs that are viable for the treatment of hypertension in the low portion of 2.5 mg and up to the treatment of high-grade renal disappointment with the high portion of 200-400 mg [1] [2] [3] [4] [5] .
Among several strategies utilized for the estimation of torsemide highperformance liquid chromatography (HPLC) turn around stage superior generally used to approve International Council for Harmonization (ICH) rules. The motivation behind this examination was to build up a straightforward, delicate, specific, and reproducible explanatory strategy for the quantitative estimation of medication. This report portrays a particular and exact HPLC strategy for the evaluation of torsemide [6] [7] [8] .
METHODS

Preparation of standard drug solutions
Accurately 10 mg of the torsemide pure drug was weighed and transferred into 10 ml clean dry volumetric flask. The volume was made up to the mark with methanol (1000 µg/ml). One milliliter of above solution was transferred to a 10 ml volumetric flask. The volume was made up to the mark with mobile phase (100 µg/ml). Two milliliters of above solution were transferred to a 10 ml volumetric flask. The volume was made up to the mark with mobile phase to get 20 µg/ ml concentration of torsemide. The solutions were injected under the above chromatographic conditions and peak areas were measured.
Chromatographic conditions
The mobile phase consisted of methanol:water in the ratio of 90:10; contents of the mobile phase were filtered before use through a 0.45 µ membrane filter and degassed for 15 min. The mobile phase was pumped from the solvent reservoir to the column at a flow rate of 1.0 ml/min and the injection volume was 20 µl. The eluents were monitored at 287 nm. The optimized conditions are shown in Tables 1  and 2 and Fig. 1 .
Calibration of standards
Different volumes of stock solutions were accurately transferred into 10 ml volumetric flasks and diluted to mark to yield concentration range of 10-60 µg/ml for torsemide. Six solutions were prepared and the final volume was made up to the mark with mobile phase. The calibration curve was obtained by plotting the peak area against the concentration of drug shown in Table 3 .
Specificity and selectivity
Specificity is the ability of a method to discriminate between the intended analyte(s) and other components in the sample. Selectivity of the HPLC method is demonstrated by the separation of the analytes from other potential components such as impurities, degradants, or excipients. The results are shown in Table 4 and The linearity of calibration curves (peak area vs. concentration) in pure solution was checked over the concentration ranges of about 10-60 µg/ml for torsemide. The eluting time was <15 min. The regression lines relating standard concentrations of drug using regression analysis, the calibration curves were linear in the studied range and equations of the regression analysis were obtained: Y=560,937.5629x+31,681.4667, r 2 =0.9993 for torsemide.
The mean±standard deviation (SD) for the slope, intercept, and correlation coefficient of standard curves (n=3) were calculated. The represented data are shown in Table 5 and Fig. 3 .
Precision i. Repeatability: The precision of the method was evaluated by calculating the relative SD (%RSD) of peak areas of six replicate injections of standard concentrations. The average RSD of torsemide was found to be 0.47%. The results are shown in Table 6 . ii. Reproducibility: The RSD of peak areas of eight replicate injections for three different standard concentrations was calculated. The average RSD of torsemide was found to be 0.47%. The results are shown in Table 7 . iii. Intermediate precision (inter-and intraday): The precision expressed within the same laboratory on different days variability of analytical results. The RSD of peak areas of three replicate injections for three different standard concentrations was calculated. For intraday studies, the average RSD of torsemide was found to be 0.46%, and for interday studies, the average RSD of torsemide was found to be 0.25%. The results are shown in Table 8 .
Accuracy
Accuracy of the method was determined by recovery experiments. To the formulation, the reference standards of the drug were added at the level of 80%, 100%, and 120%. The recovery studies were carried out 3 times and the percentage recovery and percentage RSD of the recovery were calculated and results are shown in Table 9 .
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Assay of torsemide
Accurately 10 mg of torsemide pure drug was weighed and transferred into 10 ml volumetric flask. The volume was made up to the mark with methanol (1000 µg/ml). One milliliter of above solution was transferred into a 10 ml volumetric flask and volume was made up to the mark with mobile phase (100 µg/ml). From the above solution, 2 ml was taken into a 10 ml volumetric flask and volume was made Column temperature Ambient 6.
Volume of injection 20 µl 7.
Detection wavelength 287 nm 8.
Retention time of the drug 8.267 min made triplicate and weight of drug taken for assay was calculated. The percentage of drug found, mean and SD were calculated, as shown in Table 10 and Fig. 4 .
LOD and LOQ
The LOD and LOQ were performed on samples containing very low concentrations of analytes under the ICH guidelines. By applying the mathematical formula method, LOD was expressed by establishing the minimum level at which the analyte can be reliably detected. LOQ was considered as the lowest concentration of analyte in standards that can be reproducibly measured with acceptable precision. The LOD and LOQ values for torsemide are shown in Table 11 .
Robustness
The optimum HPLC conditions set for this method have been slightly modified for samples of torsemide dissolved in the drug matrix as a means to evaluate the method robustness. The small changes include the flow rate (± 0.1ml/min), change in the composition of mobile phase Table 12 .
System suitability
It is defined as tests to measure the method that can generate result of acceptable accuracy and precision. The system suitability was carried out after the method development and validation have been completed.
The system suitability was assessed by five replicate analyses of the drugs at concentrations of 20 µg/ml of torsemide. Parameters such as plate number (n), tailing factor, and peak asymmetry of samples were measured, as shown in Table 13 and Fig. 5 .
Forced degradation studies of torsemide
Degradation studies were carried out as per the ICH guidelines. The objective of this study was to find out the degradation products, which, in turn, help in the establishment of degradation pathways and the intrinsic stability of drug molecule. To check the selectivity of the proposed method, degradation studies were carried out using acidic, alkaline, oxidative, photo, and thermal conditions.
Procedure for forced degradation studies
To determine, whether the analytical method and assay were stability indicating or not, torsemide active pharmaceutical ingredient (API) was stressed under various conditions to conduct forced degradation studies. Intentional degradation was attempted to stress conditions of acidic (0.1 N hydrochloric acid [HCl]), alkali (0.1 N NaOH), oxidative (0.3% H 2 O 2 and 3% H 2 O 2 ), photo (sunlight), and thermal (heated at 105°C) to evaluate the ability of the proposed method to separate torsemide from its degradation products. If reasonable degradation was seen under the above conditions, the testing can be stopped at this point. However, in case, no degradation was seen under the above conditions, the drug should be subjected to higher strengths and for longer duration. If total degradation was seen after subjecting the drug to initial conditions, the strength of acid/alkali/ oxidative strength can be decreased to along with decrease in the reaction temperature.
Acid degradation
Accurately 2.5 mg of the torsemide pure drug was weighed and transferred into 25 ml clean dry volumetric flask. The drug was dissolved in small quantity of methanol and then volume was made up to the mark with 0.1 N HCl (100 µg/ml). The flask was kept aside for 15 min at room temperature. Periodically (0.15 min), 2 ml was taken in a 10 ml volumetric flask, add 5 ml of mobile phase and adjust the pH between 3 and 4 by adding 0.1 N NaOH, dilute with mobile phase up to the mark (20 µg/ml). The solution was injected under above chromatographic conditions and peak area was measured. The represented data are shown in Tables 14 and 15 .
Alkaline degradation Accurately 2.5 mg of the torsemide pure drug was weighed and transferred into 25 ml clean dry volumetric flask. The volume was made up to the mark with 0.1 N NaOH (100 µg/ml). The flask was kept aside for 15 min at room temperature. Periodically (0.15 min), 2 ml was taken in a 10 ml volumetric flask, add 5 ml of mobile phase and adjust the pH between 3 and 4 by adding 0.1 N HCl, dilute with mobile phase up to the mark (20 µg/ml). The solution was injected under above chromatographic conditions and peak area was measured. The represented data are shown in Tables 16 and 17 .
Oxidative degradation Accurately 2.5 mg of the torsemide pure drug transferred into 25 ml clean dry volumetric flask. The volume was made up to the mark with 3% H 2 O 2 (100 µg/ml). The flask was kept aside for 5 days at room temperature. Periodically (0, 1, 24, 48, 72, 96, and 120 h), 2 ml was taken in 10 ml volumetric flask and made up to the mark with mobile phase (20 µg/ml). The solution was injected under above chromatographic conditions and peak area was measured. The represented data are shown in Table 18 .
Photodegradation
Accurately 2.5 mg of the torsemide transferred into 25 ml clean dry volumetric flask. The drug was dissolved in small quantity of methanol and volume was made up to the mark with HPLC water (100 µg/ml). The flask was exposed to sunlight for 9 h. Periodically (0, 1, 3, 6, and 9 h), 2 ml was taken in 10 ml volumetric flask and made up to the mark with mobile phase (20 µg/ml). The solution was injected under the above chromatographic conditions and peak area was measured. The represented data are shown in Table 19 .
Thermal degradation of solid sample at 105°C
Accurately 300 mg of the torsemide kept in Petri dish and maintained at a temperature of 105°C in a controlled temperature oven; periodically (0, 1, 3, 6, 9, and 12 h), 2.5 mg of sample was weighed and transferred into a 25 ml volumetric flask. The drug was dissolved in small quantity of methanol and volume was made up to the mark with HPLC water (100 µg/ml). From the above solution, 2 ml was taken in 10 ml volumetric flask and made up to the mark with mobile phase (20 µg/ml). The solution was injected under the above chromatographic conditions and peak area was measured. The represented data are shown in Table 20 . Theoretical plates 4706 >2000 3.
Lalitha et al.
Peak asymmetry 1.07 ≤1.5 
RESULTS
Selection of wavelength
Wavelength for detection was selected by obtaining absorption spectra of torsemide in methanol using double-beam ultraviolet-visible spectrophotometer (Lab India). The complete spectrum of torsemide and its λ max is shown in Fig. 6 . It shows that torsemide has λ max at 287 nm. The same wavelength was used in HPLC method development where the impurities can also be detected.
Several solvent systems were tried to get good optimized conditions for torsemide.
Specificity and selectivity
Specificity is the ability of a method to discriminate between the intended analyte(s) and other components in the sample. Selectivity of the HPLC method is demonstrated by the separation of the analytes from other potential components such as impurities, degradants, or excipients.
Volume of 20 μl of working placebo sample solution was injected into the chromatograph and the chromatogram was recorded and presented below. No peaks were found at retention time of 8.267 min and drug was clearly separated from its degradants. Hence, the proposed method was specific and selective for the detection of torsemide.
The acid degradation was performed with 0.1 N HCl up to 15 min at room temperature.
The drug showed liability to acid hydrolysis at room temperature. It decomposed to an extent of 26.89% in 0.1 N HCl in 15 min.
The alkaline degradation was performed with 0.1 N NaOH up to 15 min at room temperature.
The torsemide showed liability to alkali hydrolysis at room temperature. It decomposed to an extent of 32.81% in 0.1 N NaOH in 15 min.
The oxidative degradation was first performed with 0.3% H 2 O 2 for 7 days and degradation was not observed. Further, the oxidative degradation was performed with 3% H 2 O 2 at room temperature up to 5 days.
The torsemide showed more liability to oxidative stress at room temperature. It decomposed to an extent of 9.91% in 3% H 2 O 2 in 72 h and 17.46% in 120 h. The photodegradation was performed by placing the drug solution in sunlight for 9 h.
The drug is liable to photodegradation in sunlight. The drug decomposed at an extent of 11.40% in 6 h and the degradation increased to 18.02% in 9 h.
The thermal degradation was performed by placing the powdered drug sample in controlled oven at 105°C for 12 h.
